Headline Says Downgrade, But That’s Near 300% Higher From Here!
Provention Bio (NASDAQ:PRVB) PT Lowered to $18.00 (MarketBeat).
July 7th: Provention Bio (NASDAQ:PRVB – Get Rating) had its price objective reduced by investment analysts at HC Wainwright from $25.00 to $18.00 in a research note issued to investors on Monday, The Fly reports. HC Wainwright’s price objective points to a potential upside of 294.74% from the company’s previous close.
Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Provention Bio in a research report on Friday, April 1st. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Provention Bio has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.
Shares of PRVB stock opened at $4.56 on Monday. Provention Bio has a twelve month low of $3.18 and a twelve month high of $8.04. The company has a market cap of $292.02 million, a P/E ratio of -2.76 and a beta of 2.62. The business has a fifty day simple moving average of $4.07 and a 200 day simple moving average of $5.33.
Provention Bio (NASDAQ:PRVB – Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.10. The business had revenue of $0.58 million for the quarter, compared to the consensus estimate of $0.73 million. On average, analysts anticipate that Provention Bio will post -2.07 EPS for the current year.
